In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases (MuTreg)

This is an interventional basic science trial for Autoimmune Diseases focused on measuring Autoimmune Diseases, Inflammation, Graft vs Host Disease, T-lymphocytes, Regulatory, Interleukin-2 Read More

Inclusion Criteria:

• Inclusion criteria common to all patients in different departments:
• Age18 years
• Affiliated to social security or entitled to
• Patient who has been informed of the study and has signed a free and informed consent

Inclusion criteria specific by department:

Inclusion criteria for Clinical Hematology Department:

• Patient with GVHD following allogeneic hematopoietic stem cell transplantation (HSC)
• Or with acquired bone marrow suppression
• Lymphocytosis > 0.5 G/L

Inclusion criteria for Nephrology and Transplantation department:

- Patient with systemic lupus erythematosus (ACR classification criteria)

Inclusion criteria for Neurology department:

- Patient with multiple sclerosis (criteria of Mc Donald 2017)

Inclusion criteria for Rheumatology Department:

- Patient with rheumatoid arthritis (ACR classification criteria)

Inclusion criteria for Internal Medicine-Endocrinology Department:

- Patient with Basedow disease, Hashimoto's thyroiditis

Inclusion criteria for Dermatology Department:

- Patient with vitiligo or alopecia areata or atopic dermatitis

Exclusion Criteria:

Non-inclusion criteria common to all patients:

• Patient under guardianship, curatorship or judicial protection
• Pregnant, parturient or breastfeeding woman
• Patient deprived of liberty
• Patient hospitalized without consent
• Patient admitted to a health or social institution for purposes other than research
• Minor patient
• Adult patient unable to express consent
• Refusal to participate
• Patient on AME

Non-inclusion criteria specific by department:

Non-inclusion criteria for Clinical Hematology Department:

• Ongoing treatment with high doses (>1 mg/kg/d) of systemic corticosteroid therapy
• Ongoing treatment with JAK inhibitors

Non-inclusion criteria for Nephrology and Transplantation Department:

• Ongoing treatment with doses >10 mg/d Prednisone
• Ongoing treatment with Cellcept, Endoxan, Imurel, Belimumab, Anti-CD20, Methotrexate
• Ongoing treatment with JAK inhibitors

Non-inclusion criteria for Neurology Department:

• Treatment with systemic corticosteroid therapy, Fingolimod or Teriflunomide
• Ongoing treatment with JAK inhibitors
• Lymphocytosis < 0.5 G/L

Non-inclusion criteria for Rheumatology Department:

• Ongoing treatment with doses >15 mg/d Prednisone
• Treatment with Rituximab or Tocilizumab
• Ongoing treatment with JAK inhibitors
• Lymphocytosis < 0.5 G/L

Non-inclusion criteria for Internal Medicine - Endocrinology Department:

• Ongoing immunosuppressive therapy
• Ongoing treatment with JAK inhibitors

Non-inclusion criteria for Dermatology Department:

• Ongoing treatment with Methotrexate
• Ongoing treatment with JAK inhibitors
• Ongoing treatment with doses >10 mg/d prednisone